Targeted therapy and the T315I mutation in Philadelphia-positive leukemias

Haematologica. 2007 Apr;92(4):437-9. doi: 10.3324/haematol.11248.
No abstract available

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Triphosphate / metabolism
  • Amino Acid Substitution*
  • Antineoplastic Agents / pharmacokinetics*
  • Antineoplastic Agents / therapeutic use
  • Benzamides
  • Benzene Derivatives / pharmacokinetics
  • Clinical Trials as Topic
  • Drug Delivery Systems
  • Drug Design
  • Drug Resistance, Neoplasm / genetics*
  • Fusion Proteins, bcr-abl / antagonists & inhibitors*
  • Fusion Proteins, bcr-abl / chemistry
  • Fusion Proteins, bcr-abl / genetics
  • Genes, abl*
  • Humans
  • Hydrogen Bonding
  • Hydroxamic Acids / pharmacokinetics
  • Hydroxamic Acids / therapeutic use
  • Imatinib Mesylate
  • Indoles
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / enzymology
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
  • Mutation, Missense*
  • Naphthalenes / pharmacokinetics
  • Naphthalenes / therapeutic use
  • Panobinostat
  • Philadelphia Chromosome
  • Piperazines / pharmacokinetics
  • Piperazines / therapeutic use
  • Point Mutation*
  • Protein Binding
  • Protein Kinase Inhibitors / pharmacokinetics*
  • Protein Kinase Inhibitors / therapeutic use
  • Pyrazoles / pharmacokinetics
  • Pyrazoles / therapeutic use
  • Pyrimidines / pharmacokinetics
  • Pyrimidines / therapeutic use
  • Remission Induction
  • Structure-Activity Relationship
  • Threonine / chemistry
  • Vorinostat

Substances

  • Antineoplastic Agents
  • Benzamides
  • Benzene Derivatives
  • Hydroxamic Acids
  • Indoles
  • Naphthalenes
  • ON012380
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrazoles
  • Pyrimidines
  • tozasertib
  • Threonine
  • Vorinostat
  • Imatinib Mesylate
  • Adenosine Triphosphate
  • Panobinostat
  • Fusion Proteins, bcr-abl
  • doramapimod